| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
The focus of our company is optimization of biopharmaceutical proteins for multiple applications, such as targeted drug delivery, targeted
Use Dapt to link time tracking to payroll and accounting. Monitor your profitability job by job in real time. We easily handle complex overtime rules, bonuses and incentives, and advanced business logic.
Global leader in enterprise AI powered solutions for media and entertainment. Revenue management, optimization & data intelligence software.